Login

10th International Influenza Meeting

Sep 13 – 15, 2026
University of Muenster (Castle)
Europe/Berlin timezone

Contact/Support: Orgalution GmbH

Session

Session 6: Antivirals & vaccines

Sep 15, 2026, 11:00 AM
Aula (1st floor)

Aula (1st floor)

Conveners

Session 6: Antivirals & vaccines

  • Yvonne Börgeling

Presentation materials

There are no materials yet.

  1. 174. Keynote: Antivirals against influenza viruses: where do we stand and where do we go?
    Andres Pizzorno
    9/15/26, 11:00 AM
    Oral presentation
  2. 136. Fragment-based drug discovery against the Influenza virus nucleoprotein​
    Amina Qadir (University of Oxford)
    9/15/26, 11:30 AM
    Antivirals and Vaccines
    Oral presentation

    The influenza A virus nucleoprotein (NP) is an essential and highly conserved component of the viral ribonucleoprotein (vRNP) complex, where it mediates viral RNA encapsidation and coordinates multiple steps of the viral replication cycle. Despite its essential role, NP remains unexplored as a therapeutic target.

    To identify chemical starting points for structure-based inhibitor design, we...

    Go to contribution page
  3. 92. How to control HPAIV in Poultry? Exploring Vaccine Acceptance of Poultry Farmers as a Key Element in the One Health context
    Sarah Heynen (University of Veterinary Medicine Hannover, Clinic for Poultry)
    9/15/26, 11:50 AM
    Antivirals and Vaccines
    Oral presentation

    Zoonotic highly pathogenic avian influenza viruses (HPAIV) are endemic in Europe and a threat to poultry but also mammalian health. Control strategies relied on culling of infected birds. The Delegated Regulation (EU) 2023/361 enables now the European Union member states to decide for vaccination. However, the impact of a vaccination campaign depends on the successful implementation at farm...

    Go to contribution page
  4. 110. Improving Immune Responses In Avian IAV H5 Immunization By Sustained Antigen Release Technology
    Sophie Winter (University of Turku)
    9/15/26, 12:10 PM
    Antivirals and Vaccines
    Oral presentation

    Recent global outbreaks of highly pathogenic avian influenza A(H5N1) highlight the need for vaccines that can prevent human transmission. Seqirus’s zoonotic influenza A(H5N8) vaccine (approved in 2024) protects against clade 2.3.4.4b H5N1 viruses but requires a booster, which may reduce compliance. Prolonged antigen exposure can strengthen humoral immunity; therefore, sustained antigen release...

    Go to contribution page
Building timetable...